Ipamorelin Mechanism of Action — Research Reference

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is the most receptor-selective member of the growth hormone secretagogue (GHS) class. Its defining feature in the published research is GH release without meaningful elevation of cortisol, prolactin, or aldosterone.

Receptor Target

Ipamorelin is a high-affinity agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a) — the same receptor activated by endogenous ghrelin. Unlike GHRP-2, GHRP-6, and hexarelin, its binding does not measurably cross-activate ACTH-releasing or prolactin-releasing pathways at GH-effective doses.

Signal Transduction

GHS-R1a is a class-A G-protein-coupled receptor. Ipamorelin binding produces:

1. Gαq/11 → phospholipase C-β → IP3/DAG — releases intracellular Ca²⁺ from somatotrope endoplasmic reticulum stores.
2. Gαs → adenylyl cyclase → cAMP → PKA — secondary contribution that potentiates GHRH signalling.
3. Inhibition of somatostatin tone — reduces the brake on pituitary GH release.

The convergence of Ca²⁺ mobilization and cAMP elevation on the somatotrope is what produces the synergistic GH release seen when ipamorelin is paired with a GHRH analogue (sermorelin, CJC-1295, tesamorelin).

Pharmacokinetics

Subcutaneous ipamorelin reaches peak plasma in approximately 30 minutes with a half-life near 2 hours in published primate work. The molecule is resistant to DPP-IV cleavage thanks to the N-terminal aminoisobutyric acid (Aib).

Why the Cortisol/Prolactin Profile Is Clean

GHRP-2 and GHRP-6 binding extends to receptors on corticotropes and lactotropes, producing measurable ACTH and prolactin rises. Ipamorelin's D-2-Nal/D-Phe scaffold restricts its high-affinity binding to GHS-R1a, sparing those neighbouring populations in dose-response studies.

Research Use Only. All content is for laboratory research and educational reference. Compounds discussed are not intended for human or veterinary consumption.

References

1. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561.
2. Smith RG, Van der Ploeg LH, Howard AD, et al. Peptidomimetic regulation of growth hormone secretion. Endocr Rev. 1997;18(5):621–645.
3. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45–53.